Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)

• Main Authors: Mario Valenti (Author), Luigi Gargiulo (Author), Luciano Ibba (Author), Piergiorgio Malagoli (Author), Fabrizio Amoruso (Author), Anna Balato (Author), Federico Bardazzi (Author), Martina Burlando (Author), Carlo G. Carrera (Author), Paolo Dapavo (Author), Valentina Dini (Author), Francesca M. Gaiani (Author), Giampiero Girolomoni (Author), Claudio Guarneri (Author), Claudia Lasagni (Author), Francesco Loconsole (Author), Angelo V. Marzano (Author), Martina Maurelli (Author), Matteo Megna (Author), Diego Orsini (Author), Massimo Travaglini (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world experienc...